Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 901-906

  Ciurea, Stefan O ^a   Saliba, Rima M ^a   Hamerschlak, Nelson ^a   Karduss Aurueta, Amado J ^b   Bassett, Roland ^c   Fernandez Vina, Marcelo ^c   Petropoulos, Demetrios ^c   Worth, Laura L ^c   Chan, Ka Wah ^d   Couriel, Daniel R ^e   Rondon, Gabriela ^a   Sharma, Manish ^a   Qazilbash, Muzaffar ^a   Jones, Roy B ^a   Kebriaei, Partow ^a   McMannis, John ^a   Hosing, Chitra M ^a   Nieto, Yago ^a   Champlin, Richard E ^a   Shpall, Elizabeth J ^a   De Lima, Marcos ^a   more..

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b Section of Neuro oncology   (Colombia)

^c UNIVERSITY OF TEXAS   (United States)

^d TEXAS TRANSPLANT INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

fludarabine; melphalan; reduced intensity conditioning; thiotepa; Unrelated cord blood transplant

Indexed keywords

FLUDARABINE; MELPHALAN; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYSTALGIA; DIARRHEA; DISEASE FREE SURVIVAL; DYSURIA; ENGRAFTMENT; FEMALE; HEART EJECTION FRACTION; HEMATOLOGIC MALIGNANCY; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; MALE; MORTALITY; NAUSEA AND VOMITING; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; STOMATITIS; VEIN OCCLUSION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CORD BLOOD STEM CELL TRANSPLANTATION; FEASIBILITY STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MELPHALAN; SURVIVAL RATE; THIOTEPA; TRANSPLANTATION CONDITIONING; VIDARABINE; YOUNG ADULT;

EID: 84859970110     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.631159     Document Type: Article

References (29)

1. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828-3832. (Pubitemid 19141838)
2. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-166. (Pubitemid 26249452)
3. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Infl uence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-1618. (Pubitemid 34925136)
4. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical cord blood from unrelated donors. N Engl J Med 2001;344:1815-1822. (Pubitemid 32538694)
5. Long GD, Laughlin M, Madan B, et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 2003;9:772-780. (Pubitemid 38145747)
6. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental blood transplants from unrelated donors. N Engl J Med 1998;339:1565-1577. (Pubitemid 28536131)
7. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343-1347. (Pubitemid 40170912)
8. Giralt S, Th all PF, Khouri I, et al. Melphalan and purine analogcontaining preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637. (Pubitemid 32113394)
9. Slavin S, Nagler A, Naperstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant diseases. Blood 1998;91:756-763. (Pubitemid 28078275)
10. Sanz J, Sanz MA, Saavedra S, et al. Cord blood transplantation from unrelated donors in adults with high risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010;16:86-94.
11. Rubinstein P, Dobrila L, Rosenfi eld RE, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995;92:10119-10122.
12. Przepiorka D, Martin P, Klingmann HG, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828.
13. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-259.
14. Common Toxicity Criteria. Version 3.0. Available from: Http://ctep.info.nih.gov/reporting/ctc.html
15. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Prentice RL, Kalbfl eisch JD, Peterson AV, et al. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541-554. (Pubitemid 9067879)
17. Agresti A. A survey of exact inference for contingency tables. Stat Sci 1992;7:131-153.
18. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc B 1972;34:187-202.
19. de Lima M, McMannis J, Gee A, et al. Transplantation on ex vivo expanded cord blood cells using copper chelator tetraethylenepentamine: A phase I/II clinical trial. Bone Marrow Transplant 2008; 41:771-778. (Pubitemid 351696340)
20. de Lima M, Robinson S, McMannis J, et al. Mesenchymal stem cell (MSC) based cord blood (CB) expansion (Exp) leads to rapid engraftment of platelets and neutrophils. Blood 2010;116(Suppl. 1): Abstract 362.
21. Ciurea SO, de Lima M, Cano P, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem cell transplantation. Transplantation 2009;88:1019-1024.
22. Ciurea SO, Saliba R, Rondon G, et al. Reduced-intensity conditioning using fl udarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 2010;45:429-436.
23. Lekakis L, Giralt S, Couriel D, et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant 2006;38:421-426. (Pubitemid 44340372)
24. Narimatsu H, Watanabe M, Kohno A, et al. High incidence of graft failure in unrelated cord blood transplantation using reduced-intensity preparative regimen consisting of fl udarabine and melphalan. Bone Marrow Transplant 2008;41:753-756. (Pubitemid 351587042)
25. Horwitz ME, Morris A, Gasparetto C, et al. Myeloablative intravenous busulfan/fl udarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant 2008;14:591-594. (Pubitemid 351494747)
26. Komanduri K, St John LS, de Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007;110:4543-4551. (Pubitemid 351377822)
27. Ciurea SO, Mulanovich V, Jiang Y, et al. Lymphocyte recovery predicts outcomes in cord blood and T-cell depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2010;17: 1169-1175.
28. Brunstein CG, Weisdorf DJ, DeFor T, et al. Increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006;108:2874-2880.
29. Ballen KK, Cutler C, Yeap BY, et al. Donor-derived second malignancies after cord blood transplantation. Biol Blood Marrow Transplant 2010;16:1025-1031.